"Factor Xa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
| Descriptor ID |
D015951
|
| MeSH Number(s) |
D08.811.277.656.300.760.315 D08.811.277.656.959.350.315 D12.776.124.125.400.315 D23.119.400.315
|
| Concept/Terms |
Factor Xa- Factor Xa
- Factor Ten A
- Activated Factor X
- Factor X, Activated
- Coagulation Factor Xa
- Factor Xa, Coagulation
- Blood Coagulation Factor X, Activated
- Thrombokinase
- Factor 10A
- Autoprothrombin C
|
Below are MeSH descriptors whose meaning is more general than "Factor Xa".
Below are MeSH descriptors whose meaning is more specific than "Factor Xa".
This graph shows the total number of publications written about "Factor Xa" by people in this website by year, and whether "Factor Xa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor Xa" by people in Profiles.
-
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation. 2013 Sep 10; 128(11):e172-3.
-
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013 Jan 15; 127(2):224-32.